a public good project by the
Synthesis
Company
of California

© 2026

Jeffrey S. Ross | doi.page

0 works0 citations0 h-index

Jeffrey S. Ross

SUNY Upstate Medical University(US)GlobalFoundries (United States)(US)Upstate University Hospital(US)Cancer Research Foundation(US)Foundation Medicine (United States)

Publications by Year

Research Areas

Cancer Genomics and Diagnostics, Lung Cancer Treatments and Mutations, Cancer Immunotherapy and Biomarkers, Genetic factors in colorectal cancer, Bladder and Urothelial Cancer Treatments

Most-Cited Works

→ Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden(2017)3,671 cited
→ Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing(2013)2,153 cited
→ Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy(2005)1,881 cited
→ STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma(2018)1,562 cited
→ The HER-2 Receptor and Breast Cancer: Ten Years of Targeted Anti–HER-2 Therapy and Personalized Medicine(2009)1,147 cited
→ The HER‐2/ neu Oncogene in Breast Cancer: Prognostic Factor, Predictive Factor, and Target for Therapy(1998)1,010 cited

→ Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies(2012)862 cited

→ Activation of MET via Diverse Exon 14 Splicing Alterations Occurs in Multiple Tumor Types and Confers Clinical Sensitivity to MET Inhibitors(2015)791 cited

→ Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer(2006)726 cited

→ Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Urothelial Bladder Carcinoma (PURE-01): An Open-Label, Single-Arm, Phase II Study(2018)721 cited